A lipoteichoic acid-related molecule OK-PSA is an active component of OK-432, a Streptococcus-derived anticancer immunotherapeutic agent. In the present study, we first examined the effect of OK-PSA on the maturation of dendritic cells (DCs) in vitro by using the DCs derived from 5 healthy donors and 10 patients with head and neck cancer with or without expression of toll-like receptor 4 (TLR4) or MD-2 mRNA. OK-PSA treatment effectively increased the surface expression of MHC class II, CD80, CD83, and CD86. OK-PSA-stimulated DCs secreted the cytokines that can induce helper T-cell 1 (Th1)-type T-cell response, and stimulated allogeneic T cells to produce IFN-␥ and to elicit an allogeneic antigen-specific cytotoxicity. These activities almost depended on expression of TLR4 and MD-2 genes. We next investigated the in vivo anticancer effect of intratumoral administration of syngeneic DCs followed by OK-PSA against established tumors in mice. C57BL/6 mice, which express wild-type TLR4, and C57BL/6-derived TLR4-knockout (TLR4 ؊/؊ ) mice were used. Although OK-PSA accelerated the antitumor effect of intratumoral DC administration in wild-type mice bearing syngeneic tumors, the antitumor effect of OK-PSA as well as of the combination therapy with DCs and OK-PSA was not significant in TLR4 ؊/؊ mice. Interestingly, an administration of wild-type-mouse-derived DCs followed by OK-PSA exhibited a marked antitumor effect even in the TLR4 ؊/؊ mice. These findings suggest that OK-PSA may be a potent adjuvant for local DC therapy, and that DC therapy followed by OK-PSA is able to elicit anticancer activity even in a TLR4-deficient host when TLR4 is expressed only in DCs injected intratumorally.
INTRODUCTION
OK-432, a penicillin-killed and lyophilized preparation of a lowvirulence strain (Su) of Streptococcus pyogenes (group A) that was developed by Okamoto et al. (1) , is successfully used as an immunotherapeutic agent in malignancies (2, 3) . We have also reported that OK-432-based immunotherapy exhibits a marked antitumor effect in patients with oral squamous cell carcinomas (4, 5) . It has been reported that OK-432 induces interleukin (IL)-12 and polarizes the T-cell response to a helper T-cell 1 (Th1)-dominant state in mice (6) , that local injection of OK-432 augments the Th1-type T-cell response of tumor-draining lymph node cells (7) , and that OK-432 induces lymphokine-activated killer cells that exhibit higher cytotoxic activities and have a different phenotype from the lymphokine-activated killer cells induced by IL-2 (8) . Because OK-432 is a whole bacterial preparation containing many components, it remains uncertain which of those components makes the largest contribution to the Th1-inducing and antitumor activities of the preparation. We generated an IgM mouse monoclonal antibody, TS-2, that recognizes an IFN (IFN)-␥-inducing component of OK-432, and we succeeded in isolating the IFN-␥-inducing component [lipoteichoic acid (LTA)-related molecule: OK-PSA] by affinity chromatography of a butanol extract of OK-432 on cyanogen bromide-activated Sepharose 4B bound by the TS-2 (9, 10). We have reported that OK-PSA is a far more potent inducer of Th1-type cytokines as well as killer cell activities in human peripheral blood mononuclear cells (PBMCs) than the original OK-432, and that it engages in marked antitumor activity in tumor-bearing mice (9, (11) (12) (13) (14) (15) (16) . It was clearly demonstrated that OK-PSA is an active component of OK-432. Furthermore, we have reported that Toll-like receptor (TLR) 4 signaling is involved in regulating OK-PSA-induced anticancer immunity in tumor-bearing mice (17) , and that oral cancer patients who do not express or faintly express TLR4 or MD-2 gene, did not secrete IFN-␥ and did not obtain a satisfactory therapeutic effect in response to OK-432 (5) . TLRs are transmembranal proteins and represent a newly recognized family of vertebrate pattern recognition receptors in the innate immune system (18) . Among the identified family of TLRs, TLR4 recognizes bacterial cell wall components, namely lipopolysaccharide (LPS; Ref. 19) . MD-2 acts as a significant coreceptor in the TLR4 signaling. It is physically associated with TLR4 on the cell surface, and the TLR4/MD-2 complex confers responsiveness on bacterial components (20) .
Dendritic cells (DCs) are potent antigen-presenting cells that play a central role in initiating adaptive and innate immune responses. Since their original identification by Steinman, much attention has been focused on the role of DCs in eliciting the antitumor effect and in potential therapeutic applications, and the recent insights may provide the basis for generating more effective antitumor immune responses (21) (22) (23) . In most tissues, including tumor tissues, DCs are present in an immature state. The immature DCs (iDCs) are unable to stimulate T cells and are extremely well equipped to capture antigens. The iDCs are matured by the stimulation associated with capturing antigens such as bacteria, viruses, and apoptotic cancer cells, and by other stimulating agents including LPS, tumor necrosis factor (TNF)-␣, IL-1␤ and CD40 ligand. In the primary tumor sites, the antigenbearing DCs that are followed by appropriate maturation and that strongly express CD80, CD83, CD86, MHC class I and MHC class II molecules, migrate to the paracortical T-cell-rich area of the draining lymph nodes, present antigens to T cells, and induce tumor-specific CTLs as well as Th cells (23) . The immunomodulator that can induce the maturation of human DCs appropriately in vivo and in vitro may be a useful adjuvant for DC-based immunotherapy in patients with malignant diseases.
Recently, it has been demonstrated that OK-432 stimulates mature DCs, and that DCs stimulated with OK-432 can induce antigenspecific CTLs (24 -26) . In the present study, we first examined the effects of OK-PSA in the maturation of human DCs by in vitro cells per 3 ml/well) were placed into 6-well plastic tissue-culture plates (Becton Dickinson Labware, Franklin Lakes, NJ) in RPMI 1640 containing 10% heat-inactivated FBS (Bio-Whittaker). After 2 h of incubation at 37°C, nonadherent cells were removed, and the adherent cells were cultured in RPMI 1640 containing 10% heat-inactivated FBS, granulocyte-macrophage colonystimulating factor (GM-CSF, 500 units/ml; PeproTech, London, England), and IL-4 (250 units/ml; Genzyme, Boston, MA) to generate iDCs (32) . The population of the adherent cells remaining in the wells was composed of 95.6 Ϯ 3.3% CD14 ϩ monocytes. After 6 days of the cultivation, DC-maturing agents [OK-PSA (10 g/ml), OK-432 (10 g/ml), LPS (1 g/ml; derived from E. coli 055:B5; Sigma-Aldrich), or TNF-␣ (10 ng/ml; Endogen, Boston, MA)] were added into the culture. After 2 days of additional stimulation, cells and supernatants were collected and were supplied for the following analysis. The concentrations of the DC-maturing agents were determined by the preliminary experiments (data not shown).
Flow-Cytometric Analysis of Cell Surface Antigens. Cell surface staining was performed using the following antihuman monoclonal antibodies. FITC-labeled anti-HLA-A, -B, -C (MHC class I), anti-HLA-DR, -DP, -DQ (MHC class II), anti-CD80, anti-CD83 and anti-CD86 were purchased from PharMingen (San Diego, CA). Phycoerythrin-conjugated anti-CD1a and antiCD11c were obtained from Immunotech (Marseilles, France). Isotype-matched control mouse IgG, conjugated with FITC or phycoerythrin, were also purchased from PharMingen. The cells were resuspended in PBS containing 0.1% sodium azide and 0.2% BSA and then were incubated for 30 min at 4°C with a saturating concentration of each monoclonal antibody. After the cells were washed twice, their fluorescence intensity was determined using a flow cytometer (EPICS XL-MCL; Beckman Coulter, Fullerton, CA).
Assay for Cytokines and Chemokines. Cytokines and chemokines in the supernatants of the DC cultures were measured by commercial ELISA kits. The ELISA kits for TNF-␣, IL-1␤, IL-12, macrophage inflammatory protein (MIP)-1␣, regulated-on-activation, normal-T-cell-expressed-and-secreted (RANTES; BioSource International, Inc., Camarillo, CA), IL-18 (MBL, Nagoya, Japan), MIP-1␤, and IFN-␥-inducible protein-10 (IP-10; R&D System, Minneapolis, MN) were used for the present study.
Allogeneic Mixed Lymphocyte Reaction. To evaluate the antigen-presenting ability of DCs, an allogeneic mixed lymphocyte reaction (MLR) was performed. Different numbers of irradiated (30 Gy) DCs were cultured with 2 ϫ 10 5 allogeneic T cells (Ͼ95% CD3 ϩ ) purified from PBMCs by anti-CD3-coated microbeads and a magnetic cell-sorting system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). After 5 days of cultivation, [ 3 H]thymidine (1 Ci/well) was added to the cultures. Eighteen h later, [ 3 H]thymidine uptake was measured using a liquid scintillation counter. Cell-free supernatants were harvested and stored at Ϫ80°C until the assay for IFN-␥. Human monocyte-derived iDCs, generated by cultivation with GM-CSF and IL-4 for 6 days, were harvested, and total RNA was then extracted by a modified acid-guanidinium-thiocyanate-phenol-chloroform method (34) using ISOGEN RNA extracting mixture (Nippon Gene, Toyama, Japan), according to the manufacturer's recommendations. Expression of mRNAs for TLR4, MD-2 (a coreceptor for TLR4 signaling), and glyceraldehydes-3-phosphate dehydrogenase (GAPDH), a house-keeping gene that was used as an internal control, was detected by a semiquantitative reverse transcription-PCR (RT-PCR) method. The nucleotide bases used were 5Ј-TGGATACGTTTCCT-TATAAG-3Ј as an upstream primer and 5Ј-GAAATGGAGGCAC-CCCTTC-3Ј as a downstream primer for human TLR4 (506 bp; Ref. RT-PCR band was expressed as a ratio to the density of GAPDH; relative density Ͻ 0.1 was defined as Ϫ, relative density Ն 0.1 to 0.5 was defined as Ϯ, and relative density Ն 0.5 was defined as ϩ. The identification of each amplified product was confirmed by automated DNA sequencing.
Transient Transfection. iDCs derived from patient 10, in whom TLR4 gene was not detected, were transiently transfected with 2 g of pEFBOS expression plasmid containing TLR4 gene (provided by Drs. Miyake and Akashi) using SuperFect Transfection Reagent (Qiagen, Hilden, Germany). Twenty-four h later, the iDCs were treated with OK-PSA (10 g/ml) for 48 h at 37°C; then cell surface phenotype, IL-12 production, and allogeneic T-cell stimulation to produce IFN-␥ were analyzed as described above. Our preliminary study revealed that the efficiency of transfection of DCs with the expression plasmid by using SuperFect Transfection Reagent is 50 to 60%. We concluded that this efficiency is sufficient to evaluate the role of TLR4 in OK-PSA effect.
Animals. The mutant mice deficient in TLR4 (TLR4 Ϫ/Ϫ ) with a C57BL/6 background were generated by gene targeting, as described previously (5, 37). Wild-type C57BL/6 mice were purchased from Japan SLC Inc. (Shizuoka, Japan). C57BL/6 mice express wild-type TLR4. All of the mice were maintained according to the NIH standards established in the Guidelines for the Care and Use of Laboratory Animals, 5 and all of the experimental protocols were approved by the Animal Investigation Committee of Tokushima University, Tokushima, Japan.
Preparation of Bone Marrow-Derived DCs. Bone-marrow DC culture was obtained using methods described previously (38) . Briefly, mouse bonemarrow cells were harvested from the femur and tibia of sacrificed mice. Contaminating erythrocytes were lysed with 0.83 M NH 4 Cl buffer, and lymphocytes were depleted with a mixture of antibodies (RL-172, anti-CD4; TIB-105, anti-CD8; TIB-140, anti-B220; all from the American Type Culture Collection, Manassas, VA) and rabbit complement (Accurate Chemical and Scientific Corp., Westbury, NY). These cells were cultured overnight in RPMI 1640 containing 10% heat-inactivated FBS to remove the adherent macrophages, and then nonadherent cells were placed in fresh culture medium supplemented with 1000 units/ml recombinant murine GM-CSF (PeproTech, London, England) and recombinant murine IL-4 (PeproTech) for 6 days to induce iDCs.
Protocol for in Vivo Experiments. Syngeneic LL/2 cells (5 ϫ 10 5 per mouse) were injected s.c. into the footpads of wild-type C57BL/6 and TLR4 Ϫ/Ϫ mice. Approximately 7 days after the inoculation and when tumors were ϳ40 mm 3 in volume, the mice were randomly divided into 10 groups consisting of 10 mice each, with almost equal mean tumor volumes. The mice were given iDCs (1 ϫ 10 6 ), derived from wild-type C57BL/6 or TLR4
Ϫ/Ϫ mice, intratumorally on days 7, 14, and 21 after tumor inoculation and were given 100 g of OK-PSA intratumorally on days 8, 11, 15, 18, 22, and 25. The mice were monitored twice a week, and the tumor volume was estimated by measuring tumor size and using the following formula: tumor vol-
where L represents the largest diameter and W represents the smallest diameter. On day 26, three animals in each treatment group were sacrificed; then tumor infiltrating lymphocytes (TILs) and draining lymph node cells were prepared so that their cytotoxic activities could be examined, and sera were collected to measure IFN-␥. The cytotoxic activities of TILs and draining lymph node cells were assessed by a 51 Cr-release test, as described above (33) . LL/2 cells, which are inoculated cells and thus sensitive targets for the CTLs recognizing the antigens expressed in LL/2 in the present animal model, YAC-1 cells, which are sensitive target cells for mouse natural killer cells, and Meth-A cells, which are resistant to mouse natural killer cells, were used as targets in the present 51 Cr-release assay. Statistical Analysis. The data were evaluated by using one-way ANOVA. P Ͻ 0.05 was considered significant.
RESULTS

Effect of OK-PSA on the Maturation of Healthy Donor-Derived DCs to Increase the Expression of Surface Antigens, to Produce
Cytokines and Chemokines, and to Stimulate Allogeneic T Cells. We confirmed by semiquantitative RT-PCR analysis that the DCs derived from all of the healthy donors expressed both TLR4 and MD-2 genes (data not shown). Effect of OK-PSA on the maturation of healthy donor-derived DCs was examined by the several experimental systems. Data are shown in Tables 1-3 . Two days of stimulation of iDCs with OK-PSA increased the expression of MHC class I, MHC class II, CD83, a marker of mature DCs, CD80 (B7.1), and CD86 (B7.2) costimulatory 5 Internet address: http://oacu.od.nih.gov/regs/ guide/guide2.htm.
Table 1 Effect of OK-PSA on maturation of human dendritic cells (DCs) derived from healthy donors: DC surface markers
OK-PSA (10 g/ml), OK-432 (10 g/ml), LPS a (1 g/ml), or TNF-␣ (10 ng/ml) was added into the iDC culture. Forty-eight h later, cell surface antigens of the DCs were analyzed by flow cytometry. Results are expressed as mean fluorescence intensity, and mean values of five samples are shown. SDs of all mean values were less than 10%.
Class I
Class II  CD1a  CD11c  CD80  CD83  CD86   Control  752  1504  871  975  107  52  130  OK-PSA  1486  5280  1214  984  234  126  389  OK-432  1523  3442  806  718  131  59  249  LPS  1259  2188  821  1153  142  63  215  TNF-␣  972  4285  753  1007  175  126 292 a LPS, lipopolysaccharide; TNF, tumor necrosis factor; iDC, immature DC. A, monocytes derived from head and neck cancer patients were cultured for 6 days in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4, and immature DCs (iDCs) were induced. Total RNAs isolated from the iDCs were assayed for TLR4, MD-2, and GAPDH by using a semiquantitative reverse transcription-PCR (RT-PCR) method. B, cell surface phenotype of patient-derived DCs stimulated by OK-PSA (10 g/ml) for 2 days was analyzed by flow cytometry. Ⅺ, untreated; u, OK-PSA. C, IL-12 production by patient-derived DCs stimulated by OK-PSA (10 g/ml) for 2 days was measured by ELISA. Bars, SD of triplicate samples. ‫,ء‬ P Ͻ 0.01 as compared with untreated controls. Open box, untreated; hatched box, OK-PSA. D, patient-derived DCs stimulated by OK-PSA (10 g/ml) for 2 days were cocultured with allogeneic T cells derived from another patient (DC:T ϭ 1:20) for 5 days, and then the supernatants of the cocultivation were analyzed for IFN-␥ by ELISA. Bars, SD of triplicate samples. ‫,ء‬ P Ͻ 0.01 as compared with controls when untreated DCs were cocultured with allogeneic T cells. E, the cytotoxic activities of the T cells harvested from the above allogeneic mixed lymphocyte reaction (MLR) culture were assayed against antigen-specific target cells, iDCs derived from the same donor to the DCs used in MLR, as well as against nonspecific target cells, K-562, in a 51 Cr-release test. Bars, SD of triplicate samples. ‫,ء‬ P Ͻ 0.01 as compared with untreated controls. E, untreated; F, OK-PSA. (Table 2) .
The antigen-presenting ability of the DCs was assessed by allogeneic MLR assay. Immature DCs were treated with OK-PSA, OK-432, LPS, or TNF-␣ for 2 days, and then the DCs were cocultured with allogeneic T cells. In comparison with the DCs treated with OK-432, LPS, or TNF-␣, OK-PSA-treated DCs showed a higher ability to stimulate the proliferation of allogeneic T cells (data from the allogeneic MLR culture at DC:T ratio ϭ 1:20 are shown in Table 3 ). The cell-free supernatants derived from the allogeneic MLR culture (DC: T ϭ 1:20) were analyzed for IFN-␥. IFN-␥ was markedly induced when T cells were stimulated by allogeneic DCs treated with OK-PSA as well as with OK-432. IFN-␥ production by T cells that were stimulated by DCs treated with LPS or TNF-␣ was relatively weak (Table 3) . IFN-␥ was not detected in the supernatants that were derived from the cultivation of only DCs treated with any of the stimulators, including OK-PSA (data not shown). It was suggested that most of the IFN-␥ detected in the supernatants was produced by the T cells that were stimulated with allogeneic DCs. Furthermore, T cells that were cocultured with OK-PSA-treated allogeneic DCs showed marked cytotoxic activities against allo-specific target cells (data at E:T ratio ϭ 20:1 are shown in Table 3 ) but not against the nonspecific target cells K-562 (data not shown). OK-432-treated DCs also induced CTL activities, although the activities were lower than those induced by OK-PSA-treated DCs. The CTL-inducing activities of the DCs treated with LPS or TNF-␣ were only marginal. 
Effect of OK-PSA on Maturation of DCs Derived from Head and Neck-Cancer Patients in Whom Expression
TLR4(ϩ)MD-2(Ϫ)
, and that patients 9 and 10 showed TLR4(Ϫ)MD-2(ϩ) ( Fig. 1; Table 4 ). These patient-derived iDCs induced by 6 days of cultivation with GM-CSF and IL-4 were stimulated with OK-PSA for 2 days. Data from patients 1, 6, and 9, are shown in Fig. 1 . OK-PSA stimulation increased the expression of MHC class II, CD80, CD83, and CD86 in iDCs derived from patient 1. The expression of these cell surface antigens was also increased by OK-PSA stimulation on patient 6-derived DCs but not on patient 9-derived DCs (Fig. 1B) . Although DCs derived from both patient 1 and patient 6 produced IL-12 as a result of OK-PSA treatment, IL-12 secretion by patient 1-derived DCs was greater than that by patient 6-derived DCs. No IL-12 secretion by patient 9-derived DCs was observed (Fig. 1C) . Next, these OK-PSA-treated or untreated DCs were irradiated with 30 Gy of X-ray and then were cultured with allogeneic T cells (DC: T ϭ 1:20) derived from another patient. After 5 days of the cocultivation, the supernatants were analyzed for IFN-␥. IFN-␥ was markedly induced when T cells were cocultured with patient 1-derived DCs treated with OK-PSA in comparison with patient 6-or patient 9-derived DCs (Fig. 1D) . Furthermore, the allo-specific CTL activity of the T cells harvested from the above culture was also examined. CTL activity was significantly increased only when the T cells were cocultured with patient 1-derived DCs activated by OK-PSA but not when cocultured with DCs from patient 6 or patient 9 (Fig. 1E) . Table 4 summarizes the clinical backgrounds and the results of cell surface markers, IL-12 production, and allogeneic MLR in the DCs with or without OK-PSA treatment, derived from 10 patients. Patient 1, 3, 4, and 5, in whom both TLR4 and MD-2 were expressed, had complete remission in response to OK-432 and UFT (tegafur:uracil, 1:4) in combination with radiotherapy. No complete remission was observed in the patients who showed TLR4(Ϫ) or MD-2(Ϫ). We reported that OK-432 administration induced IFN-␥ protein in the sera 
Acquisition of Responsiveness of TLR4(؊) Patient-Derived DCs to OK-PSA by Transfection with Expression Plasmid Containing
TLR4 Gene. We transiently transfected the iDCs derived from patient 10, in whom the TLR4 gene was not expressed and who did not respond to OK-PSA (Table 4) , with the expression vector including TLR4 cDNA. The treatment with OK-PSA, of the DCs transfected with the TLR4 gene significantly, increased the expression of surface molecules (MHC class II, CD80, and CD86; Table 5 ), as well as the production of IL-12 ( Fig. 2A) . Furthermore, the OK-PSA-treated DCs stimulated allogeneic T cells to produce IFN-␥ (Fig. 2B) .
Antitumor Effect of Intratumoral Administration of DCs in Combination with OK-PSA in Wild-Type and TLR4
؊/؊ Mice. We next examined the in vivo anticancer effect of intratumoral administration of DCs in combination with OK-PSA. Tumor-bearing mice were given bone marrow-derived DCs and/or OK-PSA intratumorally. Results are shown in Fig. 3 . In wild-type mice bearing LL/2 cells, the antitumor effect of DC administration alone was not significant. OK-PSA inhibited the tumor growth slightly but significantly. Intratumoral injection of DCs followed by OK-PSA resulted in marked inhibition of the tumor growth (Fig. 3A) . In TLR4 Ϫ/Ϫ mice, the antitumor effect of OK-PSA as well as of the combination therapy with DCs and OK-PSA was not significant (Fig. 3B) . Interestingly, in TLR4 Ϫ/Ϫ mice bearing LL/2, the administration of wild-type-mousederived DCs and OK-PSA exhibited a marked antitumor effect (Fig.  3C) . Both in wild-type and in TLR4 Ϫ/Ϫ mice bearing LL/2, after completion of the treatment with wild-type DCs and OK-PSA on day 25, rapid regrowth of the tumors was not observed. Untreated and TLR4
Ϫ/Ϫ -DC-injected animals were dead in 8 to 11 weeks after tumor inoculation. All of the animals treated both with wild-type DCs and with OK-PSA survived over 12 weeks after tumor inoculation (data not shown).
Cytotoxic Activities of TILs and Draining Lymph Node Cells Derived from LL/2-Bearing Mice Given DCs and/or OK-PSA.
The cytotoxic activities of TILs and draining lymph node cells derived from tumor-bearing mice that were given DCs and/or OK-PSA against the inoculated tumor cells LL/2, and against nonspecific target cells YAC-1 and Meth-A, were examined by a 51 Cr-release test (Fig.  4) . In wild-type mice, the OK-PSA treatment increased the killer-cell activities of TILs against LL/2 significantly, and further enhancement of the cytotoxic activities of TILs was induced by combination therapy with DCs and OK-PSA. Slight enhancement in the killer-cell activities of the TILs against YAC-1 and Meth-A was observed in the mice that received the therapy with OK-PSA or with OK-PSA plus DCs. There were no significant differences between mice given OK-PSA alone and those given DCs and OK-PSA. In TLR4 Ϫ/Ϫ mice, the therapy with DCs and/or OK-PSA did not increase any cytotoxic activities tested. Even in TLR4 Ϫ/Ϫ mice bearing LL/2 tumors, the cytotoxic activity of TILs against LL/2 was significantly augmented by the administration of wild-type-mouse-derived DCs in combination with OK-PSA. The cytotoxicity of TILs against YAC-1 was also Table 1) , were transiently transfected with 1.5 g of pEFBOS-hTLR4. Twenty-four h later, the immature DCs were treated with OK-PSA (1 g/ml) for 48 h at 37°C; then DC surface markers were examined, and their mean fluorescence intensity was determined using a flow cytometer. Data are shown as the mean Ϯ SD of triplicate samples. (Fig. 4) . Similar results were obtained for the cytotoxicities of draining lymph node cells (data not shown).
IFN-␥ Secretion in LL/2-Bearing Mice Given DCs and/or OK-PSA. IFN-␥ in sera from mice that received therapy with DCs and/or OK-PSA was assayed by ELISA. IFN-␥ secretion was significantly increased by DCs followed by OK-PSA in wild-type mice but not in TLR4 Ϫ/Ϫ mice. By means of the intratumoral injection of wild-type DCs in combination with OK-PSA, IFN-␥ was significantly increased even in the sera from TLR4 Ϫ/Ϫ mice (Fig. 5) .
DISCUSSION
We have reported that TLR4 signaling is heavily involved in regulating antitumor immunity induced by OK-PSA as well as by OK-432 (5, 17) . It was recently reported by several investigators that OK-432 is able to stimulate DCs into maturity in vitro (24 -26) . In the present study, we investigated by using human samples, including those from patients with head and neck cancer, as well as by using animal models, whether OK-PSA, which is an active component of OK-432, may stimulate DCs in vitro to mature or not; whether OK-PSA may augment the in vivo anticancer effect of intratumoral administration of DCs or not; and whether the signaling via TLR4/ MD-2 may be involved in the anticancer effect of local DC therapy followed by OK-PSA or not.
We demonstrated in the present in vitro experiments that OK-PSA Fig. 4 . Cytotoxic activities of tumor-infiltrating lymphocytes (TILs) derived from the mice that received the therapy with an intratumoral administration of dendritic cells (DCs) followed by OK-PSA. TILs were prepared from the mice that received local DC therapy in combination with OK-PSA, and then their cytotoxic activities were analyzed by 51 Cr-release test. LL/2, YAC-1, and Meth-A cells were used as target cells in this assay. Bars, SD of triplicate determinations. ‫,ء‬ P Ͻ 0.01, as compared with untreated controls. #, P Ͻ 0.05 as compared with untreated controls. is able to mature human iDCs derived from healthy donors, as well as those from patients with head and neck cancer. OK-PSA was more effective than LPS and TNF-␣, known DC-maturing agents, as well as the original OK-432, in the maturation of the DCs. Furthermore, OK-PSA-matured DCs markedly produced IL-12 and IL-18, as well as chemokines against Th1 cells, and induced IFN-␥ production and antigen-specific cytotoxic activity in allogeneic T cells most effectively among all of the agents tested. It was strongly suggested that OK-PSA-matured DCs might induce antigen-specific CTLs and Th1 cells strongly, by presenting antigens to T cells with promoting Th1-leading situation via induction of IL-12 and IL-18 in the local environment, especially in primary tumor sites and in draining lymph nodes. It was reported that in the local tumor sites, DC maturation and activation as well as DC migration into the tumor tissues are inhibited by Th2 cytokines such as IL-6 and IL-10, as well as by TGF-␤, released by the tumor cells (22) . OK-PSA, which is a DC-maturing agent as well as a strong Th1 inducer, may be a most potent adjuvant for DC-based antitumor immunotherapy. Actually, OK-PSA significantly augments the in vivo anticancer effect of an intratumoral administration of DCs in the present animal model. Furthermore, the fact that a rapid regrowth of the tumors was not observed after completion of the treatment with wild-type DCs and OK-PSA on day 25, strongly suggests that CTLs recognizing tumor antigen(s) expressing in inoculated LL/2 cells have been induced by the present therapy. In addition, it was elucidated that these effects of OK-PSA depend on the expression of TLR4 on the DCs injected intratumorally, at least in part. We have already reported that there are oral cancer patients who do not express or faintly express the TLR4 or the MD-2 gene, and that these patients' antitumor immunity was not enhanced in response to OK-432 or OK-PSA (5). Thus, we considered that OK-432/OK-PSA might be useful for cancer therapy in TLR4(ϩ)-MD-2(ϩ) patients. For the patients who shows TLR4(Ϫ) or MD-2(Ϫ), it may be better to change OK-432 or OK-PSA to the other immunotherapeutic agents that may be more effective for the patients who show TLR4(Ϫ) or MD-2(Ϫ), e.g., CpG-DNA(TLR9 ligand), at this point in time. In addition, it was suggested that the transfer of TLR4 and/or MD-2 gene(s) may be useful to lead OK-432 or OK-PSA to elicit an antitumor effect. However, a strategy of gene transfer that can be used in clinics has not been established. The present findings indicate that the expression of the TLR4 gene in all of the immune cells in the hosts may not be essential to augment the antitumor effect of local DC therapy followed by OK-PSA, and that the effect may be obtained if TLR4 signaling is activated only in DCs injected into the tumor tissues, even in TLR4-deficient hosts. In the present study, we did not investigate the antitumor effect of TLR4-deficient DCs and OK-PSA in wild-type mice because, in the treatment of human cancer, we do not carry out the therapy using DCs deficient in TLR4 signaling against a TLR4-expressing host. We considered that first, the intratumorally injected DCs might phagocytize tumor cells; then the OK-PSA might mature the DCs that captured the tumor cells (tumor antigens) via TLR4 signaling to induce tumor-antigen-specific CTLs, and the antitumor activity of OK-PSA might be elicited. In the future, when DC local therapy followed by OK-432 and/or OK-PSA will be in use for cancer patients in whom TLR4 signaling is deficient, the strategy by which the DCs transfected ex vivo with TLR4 and/or MD-2 gene(s) are administered intratumorally may be useful. The ex vivo gene transfer is relatively convenient as compared with the in vivo gene transfer, and a high efficiency of gene transfection may be obtained. The finding that TLR4-deficient DCs acquired the responsiveness to OK-PSA so as to mature by transfection of the TLR4 expression vector ( Fig. 2; Table 5 ), strongly supports the hypothesis described above. For an in vivo study as well as a clinical trial, we are now reconstructing an adenovirus vector containing TLR4 cDNA that should make the transfection of DCs highly efficient.
Clinical study of DC-based cancer immunotherapy has been performed in many types of malignancies. Several strategies to enhance the host responses to tumors have been developed in which syngeneic DCs are armed with tumor-specific antigens as cancer vaccines. Examples of loading DCs to initiate therapeutic antitumor responses include the following: (a) DCs pulsed with defined peptides, proteins, or tumor cell lysate; (b) DCs genetically modified to express tumor antigens; and (c) DCs fused with tumor cells (39 -41) . However, there are several problems with the above strategies, namely, (a) that the homing efficiency of CTLs induced by antigen-loaded DCs to the tumor sites may be relatively low; (b) that the tumor-specific antigen(s) have never been established in most malignancies; and (c) that it is difficult to induce antigen-specific CTLs suitable for the variety of tumor antigens in a tumor tissue. The effect of an alternative strategy, namely, intratumoral administration of iDCs, was reported in humans as well as in mice (42) (43) (44) . In this strategy, for the purpose of enhancing antigen-specific antitumor immunity, it is important to bring to maturity the DCs bearing tumor antigens in the local tumor sites. We look forward to the establishment of the adjuvant(s) appropriate for maturing DCs in vivo. OK-432, which has already been used as an immunotherapeutic agent for patients with malignancies, may be a useful adjuvant for DC-based immunotherapy; and OK-PSA, an active component of OK-432, may be more potent as an adjuvant for local DC therapy than the original OK-432.
In clinical outcome of the head and neck cancer patients described in the present report, patient 2 did not have a complete remission in response to the therapy, even though he expressed TLR4 and MD-2, and patient 10 showed partial response, even when not expressing the TLR4. Although TLR4 signaling is essential for eliciting the anticancer effect by immunotherapy with OK-432, it may be difficult for patients with head and neck cancer to attain complete remission with only OK-432 therapy. Actually, all 10 patients received therapy with OK-432 and UFT simultaneously in combination with radiotherapy. The cancer cells in patient 2 may be relatively low in the sensitivity to radiation and/or UFT, even though OK-432 is effective, and the therapy using radiation and UFT may be effective for the tumor of patient 10. We have previously reported that among 28 patients, 10 (50%) of 20 TLR4(ϩ)-MD-2(ϩ) patients became histopathologically tumor-free after the therapy, and without surgical resection.
A clinical Phase I-Phase II study of intratumoral administration of DCs in combination with OK-432 has already been started in our clinic, and a satisfactory therapeutic effect was obtained, at least in oral cancer patients in whom both TLR4 and MD-2 genes are expressed. 6 Furthermore, we are now planning a clinical study of OK-PSA. We believe that OK-PSA may be an effective immunotherapeutic agent for malignant diseases, especially as a DC-maturating agent as well as a Th1 inducer.
